Important announcement in the UK today.
gov.uk/government/news/majo...
Objective will be to get innovative drugs to patients earlier and adopt the benefit of personalised medicine as markers become available and their impact understood.
Even the role of NICE will be reviewed.
More to follow.
Zanubrutinib and water intake and sodium levelEfficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis
UK medicines regulator approves Pfizer’s ‘life-saving’ Covid pillNo evidence homeopathy is effective: NHMRC review
Groundhog Day and February blahs 
